Network News

It is a beacon in the Rhine-Neckar metropolitan region: The Heidelberg-based research company BioMed X is developing new approaches to drug development at the intersection of science and industry – currently, for example, through “XFem Labs,” a women’s health project funded by the Gates Foundation. Full Text in German below. BioMed X: Regionale Power für […]

Mannheim, 23. März 2026 Zu den Downloads Mit einer Investition von 90 Millionen Euro stärkt Roche den Standort Mannheim als ein zentrales Drehkreuz im globalen Distributionsnetzwerk für Diagnostika des Unternehmens. Das neue Distributionszentrum für Europa umfasst eine Fläche von rund 16.300 Quadratmetern, das entspricht etwa zweieinhalb Fußballfeldern. Hochmoderne Automatisierungstechnik und nahtlos vernetzte IT- und Transportsysteme […]

Heidelberg, March 18, 2026 – At yesterday’s meeting of the Board of Trustees of the German Cancer Research Center (DKFZ), the board decided to become the fifth shareholder of InnovationLab GmbH (iL). In addition to BASF SE and HEIDELBERG (Heidelberger Druckmaschinen AG), the Karlsruhe Institute of Technology (KIT) and the Ruprecht-Karls University of Heidelberg are […]

On March 17, 2026, the Heidelberg Cell and Liquid Biobank’s large-scale sample repository was inaugurated on the Heidelberg Medical Campus. More than five million patient samples can be stored automatically in two systems in accordance with high-quality standards. The new large-scale sample repository thus serves as a central infrastructure for patient-oriented research at the Heidelberg […]

Brain tumors can hijack the nervous system, tap into its activation signals, and thereby accelerate their growth. For these groundbreaking discoveries regarding the role of the nervous system in the growth of brain tumors, the Paul Ehrlich Foundation honored Dr. Dr. Varun Venkataramani, a neuroscientist at Heidelberg University’s Faculty of Medicine and a neuro-oncologist at […]

How can artificial intelligence support medical imaging diagnostics in the future and significantly improve patient care? Researchers led by Lena Maier-Hein (German Cancer Research Center, DKFZ, and NCT Heidelberg) have developed an innovative concept to address this question. The Carl Zeiss-Stiftung is funding the MEDAL* project with a total of three million euros. Experts and […]

Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to venglustat, a novel, investigational oral glucosylceramide synthase inhibitor (GCSi), for the treatment of neurological manifestations of type 3 Gaucher disease (GD3), a rare lysosomal storage disorder. The designation is based on […]

Ladenburg, Germany, 18 March 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that its partner Huadong Medicine Co., Ltd., Hangzhou, China, (SZ 000963; Huadong) has reached a development milestone under the terms of the license agreement from February 2022. With the dosing of the first patient […]

The University Children’s Hospital Zurich and the Thomas and Doris Ammann Foundation have awarded the Thomas and Doris Ammann Prize to Stefan Pfister, Director of the Hopp Children’s Cancer Center Heidelberg (KiTZ), Head of Department at the German Cancer Research Center (DKFZ), professor at the Heidelberg Medical Faculty of Heidelberg University, and pediatric oncologist at […]